In summary, extended follow-up from the phase II BYLieve study support the sustained benefit of alpelisib plus endocrine therapy in patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. Here, PIK3CA is linked to breast carcinoma.